BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Sosei Group Corporation 

4F Ichiban-cho FS Building
8 Ichiban-cho, Chiyoda-ku
Tokyo    102-0082  Japan
Phone: 81-0-3-5210-3290 Fax: 81-0-3-5210-3291


SEARCH JOBS








 Company News
Sosei Group Corporation Signs Distribution Agreement With FUJIFILM Pharma For Commercialization Of SO-1105 2/4/2014 9:15:33 AM    More...
Sosei Group Corporation: Once-Daily Ultibro® Inhalation Capsules (QVA149) For COPD Launched In Japan 11/20/2013 9:36:38 AM    More...
Sosei Group Corporation's First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Approved for the Treatment of COPD in Europe 9/23/2013 9:44:18 AM    More...
Sosei Group Corporation: First in Class Once-Daily Dual Bronchodilator Ultibro Inhalation Capsules (QVA149) Approved for the Treatment of COPD in Japan 9/20/2013 10:14:33 AM    More...
Sosei Group Corporation Announces Initiation of Phase III Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis 3/12/2013 10:00:41 AM    More...
Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149 9/4/2012 11:52:42 AM    More...
Sosei Group Corporation Announces Successful Completion of Phase I Study for SO-1105 for the Treatment of Oropharyngeal Candidiasis 7/2/2012 9:28:38 AM    More...
Sosei Group Corporation Release: Once-daily Seebri® Breezhaler® Receives Positive CHMP Opinion to Treat COPD Patients in the EU 6/25/2012 11:55:44 AM    More...
Sosei Group Corporation's QVA149 ILLUMINATE Phase III COPD Study Meets Primary Endpoint and Clarification of Anticipated Timing of US Filings for NVA237 and QVA149 4/24/2012 6:52:33 AM    More...
Sosei Group Corporation Release: QVA149 Phase III COPD Studies Met Primary Endpoints 4/2/2012 11:18:22 AM    More...
123

//-->